Mainz Biomed EBITDA Margin 2021-2023 | MYNZ

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Mainz Biomed ebitda margin from 2021 to 2023. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Mainz Biomed EBITDA Margin 2021-2023 | MYNZ

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Mainz Biomed ebitda margin from 2021 to 2023. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.8B
Regeneron Pharmaceuticals (REGN)	$126.4B
Vertex Pharmaceuticals (VRTX)	$124.2B
Gilead Sciences (GILD)	$103.4B
Bristol Myers Squibb (BMY)	$100.3B
CSL (CSLLY)	$97.4B
GSK (GSK)	$88.2B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Argenex SE (ARGX)	$31.2B
BioNTech SE (BNTX)	$29.7B
Biogen (BIIB)	$28.9B
Moderna (MRNA)	$27.7B
Illumina (ILMN)	$20.7B
BeiGene (BGNE)	$19.2B
Genmab (GMAB)	$17.5B
BioMarin Pharmaceutical (BMRN)	$13.4B
Vaxcyte (PCVX)	$13B
Incyte (INCY)	$12.8B
Insmed (INSM)	$12.6B
Exact Sciences (EXAS)	$12.6B
Sarepta Therapeutics (SRPT)	$12B
Bio-Techne Corp (TECH)	$11.9B
QIAGEN (QGEN)	$10.4B
Legend Biotech (LEGN)	$9.3B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.5B
Intra-Cellular Therapies (ITCI)	$7.9B
Exelixis (EXEL)	$7.9B
Halozyme Therapeutics (HALO)	$7.8B